Tslil Lahav, head of Israeli Economic and Trade Mission in Taipei, introduced Israel A briefing on Israeli startup resources and investment was held by NTU Industry Liaison Office (ILO) at the Taiwan X Israel Center (TXI Center) on the afternoon of October 31, inviting Tslil Lahav, head of Israeli Economic and Trade Mission in Taipei, Revital Shpangental, representative of Haifa University, a number of Israeli economic and trade figures, Pai-Chi Li, R&D chief of National Taiwan University, David Peng, CEO of NTU ILO, and corporate members of NTU ILO. This event looked closely on Israel’s startup resources, education, and investment environment, providing professional insights on industrial complementarity between Taiwan and Israel. With questions from members of NTU ILO. Tslil Lahav specifically mentioned that Israel itself has a very strong start-up energy. The feature lies in the investors. Both investors and venture company are not afraid of failure and they grasp every opportunity. Which is something Taiwan worth to learn. Besides, Israel is highly focus on research and development, they are No.1 in the world in R&D investments as % of GDP, which is very astonishing. More than 50% of the goods and services exported from Israel are high-tech industries related, and these highlights are complementary to the industry between Taiwan and Israel. Tslil Lahav answered questions from NTUILO members With questions from members of NTUILO, Lahav and Li pointed out that combining Israel’s startup technology and Taiwan’s expertise in system integration, membership of NTU ILO would accelerate the development of Taiwan’s industry and create new business opportunities under waves of US-China trade war and global IT revolution.   Pai-Chi Li, R&D chief of National Taiwan University, emphasized the advantages of Taiwan industries  

National Chung Hsing University cerebrates a-hundred-year anniversary with ultimate business opportunity November of 2019 is the month of NCHU. Cross-linkage of the cooperation of NCHU and the Analysis and Promotion of Agricultural Biotechnology Office (APAB), 2019 Agricultural Biotechnology Excellence Innovation Forum and Match-making Conference was co-host this event in the international conference room of NCHU library building on 7 th Nov. NCHU was established based on the agricultural specialty. The R&D of agricultural technology has been accumulated over a century, and continued to expand into the fields of food technology and health science. NCHU President, Mr. Fuh-Sheng Shieu addressed that as a top multidisciplinary university,  NCHU should not only be limited to the number of teaching or pursuing the numbers of journal publication, but also fulfill university social responsibility and strengthen the link between industry and the university. Until now, the cases proposed by NCHU professors are quite unique and successful industry-university cooperation model. Taiwan has great advantages in the agricultural biotechnology industry. Thus, we wish to break through the bottleneck in the world stage to create more opportunities, especially through this match-making activity.      This activity was hosted by the Analysis and Promotion of Agricultural Biotechnology (APAB), and NCHU GLORIA and General Center for Academia-Industry Collaboration are co-organizers. It aimed at promoting and presenting NCHU cooperation achievements in productions of agriculture, food and biotechnology, and biomedical health. The speeches activities include the topic of “The produce and prospects from university to business enterprise” by the Academician Prof. Dr. Chiu-Chung Young, and the topic of "Probiotics products and their application techniques for protecting crop health" by the NCHU vice-president Jenn-Wen Huang. Besides, there are also several speeches shared by NCHU outstanding professors, such as the Dean of the College of Agriculture and Natural Resources, Professor Fuh-Jyh Jan, the Dean of College of Engineering, NCHU, Dr. Gou-Jen Wang, and the Dean of College of Innovation and Industry Liaison, Professor David Wang, for their R&D technology development and achievement. Moreover, 2019 Agricultural Biotechnology Excellence Innovation Forum and Match-making Conference also invited lots of enterprises, include NCHU GLORIA members TCI CO., LTD. and Maxluck Biotech Co., Ltd., to present the top R&D results and industry-university cooperation values for more opportunities with NCHU professors. NCHU GLORIA and General Center for Academia-Industry Collaboration endeavor to collect campus professors R&D achievements to the Analysis and Promotion of Agricultural Biotechnology (APAB). On 7 th , Nov., there are more than 30 match-making conferences totally. How successful first step of industry-university cooperation. Furthermore, NCHU GLORIA members, such as JH Biotech, Inc., Good Agricultural Modernization Agricultural Science and Technology Co., Ltd., Diamond Nano-Biochem. Co., Ltd., Healthmate Co., Ltd., and FWUSOW Industry, were invited to exhibit their agricultural biotechnology related production and R&D achievement for having more significant business opportunities.  

2019/10/26 NBRP Biomed Startup Challenge Pitch Day The NBRP Biomed Startup Challenge, a collaboration between the Academia Sinica Biomedical Translation Research Center and AstraZeneca (AZ) and Taipei Medical University, this program joint AZ's global iDream program and resources from the Taipei Medical University. Particularly for the topic such as Oncology, Cardiovascular / nephrology / metabolic diseases, Respiratory diseases,Digital health, In total 31 groups of Startup teams registered from local and abroad, there are selected 16 outstanding teams through the company review and 1on1 interview and participate in the final selection on Pitch Day on October 26.   Among the short-listed selection teams, there are startup use the Internet of Things technology to solve the pathology tracking and management, as well as the application of digital technology and big data to improve the accuracy of physician diagnosis, and studying in the field of oncology, expecting to provide not only personalized and precise treatments and new drugs in the future, but also significantly improve anti-cancer effects through digital medicine for preventive testing and post-operative tracking.   In this Pitch Day competition, Wu, Han-Zhong, Acting Director of the National Biotechnology Research Park Biomedical Translation Research Center, Justin Chin,  the President of Taiwan AstraZeneca Co., Ltd., Chen, Mei-Ling, Chairman of the National Development Council, and Lin, Chien-Huang, President of Taipei Medical University, gave speech. Numbers of important VIP guests also attended the event, including Vice President Chen, Chien-Jen, Vice President of the Ministry of Science and Technology Shieh, Dar-Bin, President of the Academia Sinica James C. Liao, AZ Global Business Development Operations Senior Vice President Shaun Grady; and Taipei Medical University Chairman Chang, Wen-Chang, National Health Research Institutes (NHRI), Liang, Kung-Yee, the representative of the British Office in Taiwan, Catherine Nettleton, and the academician of the Academia Sinica, Wang, Hui-Zhen, and others. Wu, Han-Zhong, Acting Director of the National Biotechnology Research Park   Wu, Han-Zhong, Acting Director of the National Biotechnology Research Park, said that after 10 years of planning, the Biotech Park will is completed for about a year. With the help of AS-BioTReC, the Biotechnology Park has abundant biomedical research and development energy, and this International Biomedical Accelerator Program is one of the important strategies. This biomedical accelerator cooperation program has AZ and Taipei Medical University assisted in the selection, promotion, evaluation and course training to accelerate the development of research and results to the international. Justin Chin, the President of Taiwan AstraZeneca Co., Ltd   Justin Chin, the President of Taiwan AstraZeneca Co., Ltd, said that AZ not only leads the world in new drug research and development, but also invests 25% of its revenue in innovative research, and attaches great importance to innovation science. In the past three years, AZ has introduced five drugs related to cancer, respiratory and cardiovascular diseases, and it is expected to bring better treatment to patients. In the past five years, the investment in clinical trials has exceeded NT$1.3 billion. In the past three years, the clinical scale has ranked first in Taiwan. Among the global biomedical research and development programs iDREAM launched by AZ, Taiwan is the fifth country to join the establishment. AZ will spare our best effort to become the international coaching energy of the winning team, and jointly promote the integration of biomedical research and development. Lin, Chien-Huang, President of Taipei Medical University   Taipei Medical University plays a pivotal role in clinical research and study. President Lin, Chien-Huang of Taipei Medical University said: The medical system of the Seventh Hospital of Taipei Medical University has a wealth of clinical and innovative resources, providing teams to conduct a one-stop commercial guidance for complete medical treatment. In the short term, the product results and company value will be greatly improved, and through the Taipei Medical University Accelerator, for market trends, regulatory strategies, clinical evaluation, IT integration and other examples, as well as one-on-one consultation with medical consultants, clinical database resources, international resources. Linking, accelerating team product development and entering the market. It has successfully coached many local and foreign biomedical startups to conduct industry and university cooperation and enter to the clinical market. After the establishment of the biomedical industrial park in the future Shuanghe Hospital Campus, it will become an important base to further promote the success of the startup company. At present, the Taipei Medical University Accelerator has cooperated closely with internationally renowned university accelerators such as Stanford Biodesign, UCSF QB3, StartX, and internationally renowned entrepreneurial accelerators such as 500 Startups. It also recruits newcomers with the flank accelerator and the US MassChallenge team. Chen, Mei-Ling, Chairman of the National Development Council   Chen, Mei-Ling, Chairman of the National Development Council pointed out that Taiwan's medical system has rich clinical trial energy and first-class medical professionals which has won world recognition. In 2019, the World Economic Forum ranked Taiwan as the 12th medical advanced among 144 national economies. The country's ability to innovate is also among the four major innovation countries in the world with Germany, the United States and Switzerland. National Development Council is to create a good investment environment. Last year, the Executive Yuan passed the “Optimization of New Investment Action Plan” developed by the National Development Council. Through five major strategies, it created a new early-stage fund to enable the government to integrate angels. Investment, and has invested more than 2 billion Taiwan dollars in 57 new industries, and also became a new venture through talent cultivation, new regulatory frameworks, relaxation of cell therapy technology and telemedicine, and creation of multiple outlets. The team's partners lead them to connect with the international market. Vice President Chen, Chien-Jen   Vice President Chen, Chien-Jen also came to the scene specially. He said that the biomedical industry is a government that has been vigorously promoting the use of the three main axes of connecting the land, connecting the world, and connecting the future. The three main axes are to recruit talents, adjust regulations, and raise funds to improve. The entire industrial ecosystem is committed to building Taiwan into a major city for biomedical research and development in Asia-Pacific. Currently, in Taipei, Hsinchu, Kaohsiung and other regions, special medical biotechnology settlements have been established. Among them, the National Biotechnology Research Park is the most important leader. This event will also link foreign resources and help Taiwan's biomedical innovations to leap to the international arena.   Chen, Chien-Jen also pointed out that Taiwan's current biomedical industry has grown by more than 5% in both turnover and investment cases. The combined revenue of listed cabinet companies has reached an annual increase rate of 11%. The market value has also reached 890.4 billion, so in the near future, Taiwan's biotechnology industry is expected to become the next trillion industry. President of the Academia Sinica James C. Liao President of the Academia Sinica James C. Liao, said that more than a month ago, the Academia Sinica BioTReC was formally established as a unit of the Academia Sinica in the National Biotechnology Research Park. It will serve the manufacturers together with the Ministry of Health and Welfare, Ministry of Economic Affairs and Ministry of Science and Technology. During the incubation, 11 manufacturers have entered the market, and 12 manufacturers is also signing up. It is expected that a 50% occupancy rate will be reached by the end of this year. In the future, it will actively coach manufacturers to find new companies with innovation, leadership and execution capabilities. And committed to the industry and academic cooperation. In addition, I also invited international companies to enter the country, first signing with AstraZeneca in the UK, and then signing with iPark, Takeda from Japan, and Amgen of the United States, introducing the pharmaceutical experience of international companies to the country. As the National biotechnology research park becomes more mature, it will achieve a clustering effect, making the ecosystem of innovative research more and more complete. Vice President Chen, Chien-Jen and Taipei Medical University Chairman Chang, Wen-chang 8 enlisted Startup team In order to allow the participating teams to obtain more professional evaluation suggestions, Pitch Day invited AstraZeneca, global senior vice president and director of the Asian Department of Medicine and the head of the Taipei Medical University. The director of the Big Data Technology and Management Institute, the director of the Shuanghe Hospital, the CEO of the Biotechnology Development Center of the Foundation, and the co-founder of ixensor, etc., as judges panel, The three major scoring criteria were practical feasibility, proposal integrity and innovation. In the final there are 8 selected teams: AESOPTechnology, ATP BioPharm, CancerfreeBiotechLtd, Guzip Biomarkers Corp, cytena Bioprocess Solutions Co., Ltd., TMU KHC team, NHRI-New Co (ABT), Academia Sinica - Amnion Biosciences.   Among the 8 selected winners, 4 groups were the from Taipei Medical University, AESOPTechnology, ATP BioPharm, Guzip Biomarkers Corp, TMU KHC team, respectively, in AI drug safety applications, small molecule new drug development, endometrial cancer test reagent development and cancer. The field of dual-function antibody development has been unanimously affirmed. 2019 NBRP Biomed Startup Challenge

NCKU President Jenny Su (left) signed an MOU with her counterpart, CTCI Group Chairman John T. Yu, in Taipei The Global Research & Industry Alliance of National Cheng Kung University (GLORIA NCKU) is set to work closely with world renowned engineering service provider CTCI Group after an MOU was signed between the two parties on Oct. 31.   Such cooperation will include various fields, such as smart engineering, smart factories, green industry, big data analyses and many others, the alliance said in a statement recently.   Jenny Su, NCKU President, signed the pact with her counterpart, John T. Yu, CTCI Group Chairman, at a ceremony witnessed by many heavyweights from the two parties in Taipei.   “We believe the tie up and application exchange can speed up our intelligent transformation,” said Yu, adding that his group is determined to improving its engineering integration capabilities and cultivating engineering talents.   Su echoed his remarks, saying that her school is CTCI’s best partner in Taiwan as it also focuses heavily on smart technology and its application. The school’s nine colleges and over 80 research centers will be deeply involved in this project, with the aims of forging “the most trustworthy global engineering service provider team,” according to the Tainan-based university.   CTCI is a world renowned Engineering, Procurement, and Construction (EPC) services provider. Founded in 1979, CTCI emerged as the leader in Taiwan's hydrocarbon processing industry and has been an active player in the international power, environmental, transportation and industrial markets. The multinational group boasts over 7,000 employees worldwide, and has been selected in the Emerging Markets index of the Dow Jones Sustainability Indices for five years in a row.